Possible Interaction: Lentinan and Aldesleukin

“The generation of lymphokine-activated killer (LAK) activity, induced by in vitro activation of PBM with interleukin 2 (IL 2), was significantly augmented 5 days after a single intravenous dose of 2 mg lentinan , when compared with that before lentinan injection.”

“On the other hand, percentage of CD8+CD11- cells were significantly increased and production of IL-2 was markedly enhanced after the local injection of Lentinan.”

“The results indicated that lentinan of above mentioned concentrations did not obviously promote the lymphocyte proliferation, but increased the secretion of IL-2 and IFN-γ and enhanced the expression of lymphocyte surface markers CD4 and CD8 in microgravity environment.”

“Improvements of antitumor effects by the combination of lentinan and IL-2 were also observed in the MBL-2/B6 and S908.D2/B10.D2 systems.”

“From these results we conclude that IL-2 and lentinan in combination are more effective than either one alone for inducing destruction of pulmonary metastases.”

“with lentinan became cytotoxic on in vitro treatment with IL-2.”

“… IL-2 … lentinan was also observed in mice bearing spontaneous lung micrometastases: neither IL-2 (<5×104 U/mouse) nor lentinan (<2.5 mg/kg) alone … a therapeutic effect, but multiple injections of IL-2 with a single injection of lentinan resulted in significant inhibition of spontaneous pulmonary metastases.”

“Furthermore, combination therapy with lentinan and IL-2 achieved complete tumour regression in all the mice transplanted with S908.D2 progressed tumour lines, although IL-2 alone did not show any anti-tumour effects in either the S908.D2 parental or progressed lines.”

“Synergistic effects were observed between pre‐ and post‐operative treatments with lentinan and IL‐2 : 8 of 12 mice were completely cured.”

“3) Preoperative endoscopic intratumoral injection combined IL-2 and Lentinan or OK-432 induced immunocytes including antigen-presenting cells in the site of the gastric cancer, and increased the IL-2R and the LAK activity of PBL.”

“Furthermore, combined administration of lentinan and IL-2 was found to augment the endogenous LAK activity even in the tumor bearer, and show a substantial inhibition of tumor growth and a significant increase in survival rate in the C3H/HeN/MM46 system.”

“Surface marker analysis of endogenous … a combined administration of lentinan … IL-2 were all NK-type LAK cells, which express asialo-GM1 and lack T3, Thy-1 and Lyt2, whereas LAK … NK-type LAK and T-type LAK cells, which express T3 and Thy-1, and lack asialo-GM1.”

“Oral administration of LTN apparently modulates the systemic immune function through T cell stimulation , especially Th cells, but continued administration may induce a tolerance to the effect of LTN.”